Loading...

Alexa Fluor® 647 Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Alexa Fluor® 647, Streptavidin-AF647
Ave. Rating
Submit a Review
Product Citations
publications
Strepavidin_A647_Antibody_FC_013114
Human peripheral blood lymphocytes were stained with biotinylated CD3 (filled histogram) or biotinylated mouse IgG1 isotype control (open histogram), followed by SAV-Alexa Fluor® 647.
  • Strepavidin_A647_Antibody_FC_013114
    Human peripheral blood lymphocytes were stained with biotinylated CD3 (filled histogram) or biotinylated mouse IgG1 isotype control (open histogram), followed by SAV-Alexa Fluor® 647.
See Alexa Fluor® 647 spectral data
Cat # Size Price Quantity Check Availability Save
405237 100 µg $206
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Alexa Fluor® 647 is useful for detecting biotinylated antibodies. The excitation of Alexa Fluor® 647 by 633 nm / 635 nm laser light induces a light emission maximum of 668 nm.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin was conjugated with Alexa Fluor® 647 under optimal conditions.
Concentration
0.5 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-Alexa Fluor® 647 solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the Alexa Fluor® 647 conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633 nm / 635 nm.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Streptavidin-Alexa Fluor® 647 is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-Alexa Fluor® 647 is 60 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Shade KT, et al. 2015. J Exp Med. 212:457. PubMed
Product Citations
  1. Janeczek A, et al. 2017. Nanomedicine. 10.2217/nnm-2016-0386. PubMed
  2. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  3. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  4. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  5. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  6. Schiesser JV, et al. 2021. Sci Rep. 11:8315. PubMed
  7. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  8. Noreng S, et al. 2022. Nat Commun. 13:6079. PubMed
  9. Biram A, et al. 2020. Cell Rep. 30:1910. PubMed
  10. Needham BD, et al. 2022. Nature. 602:647. PubMed
  11. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  12. Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed
  13. Zhou D, et al. 2022. Nat Commun. 13:5174. PubMed
  14. Zhang R, et al. 2021. MAbs. 13:1904546. PubMed
  15. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  16. Wang Z, et al. 2021. bioRxiv. . PubMed
  17. Yap K, et al. 2022. STAR Protoc. 3:101139. PubMed
  18. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  19. Charles TP, et al. 2021. PLoS Pathog. 17:e1009257. PubMed
  20. Van Den Berge N, et al. 2019. Acta Neuropathol. 138(4):535. PubMed
  21. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  22. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  23. Gilpin TE, et al. 2021. J Immunol. 207:1065. PubMed
  24. Van Simaeys D, et al. 2022. Nat Commun. 13:1815. PubMed
  25. Biram A, et al. 2020. Bio Protoc. e3562:10. PubMed
  26. Lee M, et al. 2020. Elife. :9. PubMed
  27. Duong BTV, et al. 2020. EBioMedicine. 61:103031. PubMed
  28. Kulkarni N, et al. 2017. Eur J Appl Physiol.. 10.1007/s00421-017-3704-z. PubMed
  29. Wang X, et al. 2021. EMBO J. 40:e105926. PubMed
  30. Wang Z, et al. 2021. Nature. 592:616. PubMed
  31. Puentes-Mestril C, et al. 2021. J Neurosci. 41:5386. PubMed
  32. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  33. Wang Z, et al. 2021. Nature. 595:426. PubMed
  34. Lederer K, et al. 2022. Cell. . PubMed
  35. Wang Z, et al. 2020. Elife. 9:00. PubMed
  36. Li D, et al. 2020. Immunohorizons. 0.661805556. PubMed
  37. Gaebler C, et al. 2020. bioRxiv. . PubMed
  38. Plewes MR, et al. 2020. FASEB J. 5299:34. PubMed
  39. Chmielewski M and Abken H 2017. Cell Rep.. 10.1016/j.celrep.2017.11.063. PubMed
  40. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  41. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  42. Frohlich J, et al. 2020. Aging (Albany NY). 12:20024. PubMed
  43. Pabbisetty S, et al. 2016. Proc Natl Acad Sci U S A. 113: E4662 - E4670. PubMed
  44. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed

Related FAQs

There are no FAQs for this product.
Go To Top Version: 5    Revision Date: 06/18/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account